We are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own partnerships of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). The Company has collaborated or is collaborating with Amgen, Pfizer, AstraZeneca, and Roche to develop Accurins based on therapeutic payloads from their product pipelines.
View all » Recent Releases
View all »Events & Presentations
Aug 7, 2014 at 8:30 AM ET
BIND's Second Quarter 2014 Financial Results
Aug 13, 2014 at 10:55 AM ET
Wedbush 2014 Life Sciences Management Access Conference